0001493152-23-032472.txt : 20230913 0001493152-23-032472.hdr.sgml : 20230913 20230913160123 ACCESSION NUMBER: 0001493152-23-032472 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230913 FILED AS OF DATE: 20230913 DATE AS OF CHANGE: 20230913 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Galmed Pharmaceuticals Ltd. CENTRAL INDEX KEY: 0001595353 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981147233 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36345 FILM NUMBER: 231252633 BUSINESS ADDRESS: STREET 1: 16 ZE'EV TYOMKIN ST. (4TH FL.) CITY: TEL AVIV STATE: L3 ZIP: 6578317 BUSINESS PHONE: 97236938448 MAIL ADDRESS: STREET 1: 16 ZE'EV TYOMKIN ST. (4TH FL.) CITY: TEL AVIV STATE: L3 ZIP: 6578317 6-K 1 form6-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of September 2023

001-36345

(Commission File Number)

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

16 Tiomkin St.

Tel Aviv 6578317, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover

Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On September 13, 2023, Galmed Pharmaceuticals Ltd. (the“Company”) convened a Special General Meeting of Shareholders (the“Meeting”), however, the Meeting was adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Meeting will be reconvened on Wednesday, September 20, 2023 at 5:00p.m., Israel time at the Company’s offices located at 16 Tiomkin St., Tel Aviv 6578317, Israel.

This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration No. 333-206292 and 333-227441) and the Company’s Registration Statement on Form F-3 (Registration No. 333-254766).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Galmed Pharmaceuticals Ltd.

Date: September 13, 2023	By:	/s/ Allen Baharaff
		Allen Baharaff
		President and Chief Executive Officer